methyl 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylate | 160693-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: methyl 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylate
• CAS: 160693-52-7
• 化学式: C₁₂H₁₂BrNO₃
• 分子量: 298.136
• InChiKey: YSILPCFQYCQJDY-UHFFFAOYSA-N

物化性质

• 沸点：
  465.7±40.0 °C(Predicted)
• 密度：
  1.534±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylate 在 盐酸 、 一水合肼 作用下， 以 水 、 异丙醇 为溶剂， 反应 4.0h， 生成 (4-bromophenyl)-5-oxo-N'-(4-oxo-1,4-dihydronaphthalen-1-ylidene)pyrrolidine-3-carbohydrazide
  参考文献：
  名称：

  5-氧代-1-苯基吡咯烷-3-碳酰肼与1,4-萘醌衍生物的反应及所得产物的性质

  摘要：

  N '-（4-Oxo-1,4-二氢萘-1-亚甲基）-1-苯基-5-氧吡咯烷-3-碳酰肼和N '-（3-甲基-4-氧代-1,4-二氢萘-1 -亚苯基）-1-苯基-5-氧吡咯烷-3-碳酰肼通过5-氧代-1-苯基吡咯烷-3-碳酰肼与1,4-萘醌或2-甲基-1,4-萘醌的反应合成。使用碘乙烷获得上述产物的烷基化类似物。5-氧代-1-苯基吡咯烷-3-碳酰肼与2,3-二氯-1,4-萘醌的相互作用随后形成N '-（3-氯-1,4-二氧代-1,4-二氢萘-2-基）-1-苯基-5-氧吡咯烷-3-碳酰肼。所有这些化合物的特征均使用1 H，1313 C NMR，IR和质谱。测试了一些新化合物的抗微生物和抗真菌活性。

  DOI：

  10.1007/s11164-011-0306-y
• 作为产物：
  描述：

  1-(4-溴苯基)-5-氧代吡咯烷-3-羧酸 在 硫酸 作用下， 以 甲醇 为溶剂， 以91%的产率得到methyl 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylate
  参考文献：
  名称：

  [EN] LACTAMS AS INHIBITORS OF ROCK
  [FR] LACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE RHO-KINASES (ROCK)

  摘要：

  本发明提供了化合物的结构式（I）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包括这些化合物的药物组合物以及使用这些药物治疗心血管、平滑肌、肿瘤、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。

  公开号：

  WO2016144936A1

文献信息

• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS DE GPR40 À BASE DE PYRROLIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015171757A1

  公开（公告）日：2015-11-12

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体、药用盐、多晶型或溶剂化物，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof
  申请人：Jaehne Gerhard

  公开号：US20110046105A1

  公开（公告）日：2011-02-24

  The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  该发明涉及式(I)的化合物，其中基团R和R'、A、D、E、G、L、p以及R1到R10具有所述的含义，以及它们的生理兼容盐。所述化合物可作为抗肥胖药物，例如。
• Lactams as inhibitors of rock
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10112929B2

  公开（公告）日：2018-10-30

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物：或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• Pyrrolidine GPR40 modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10301260B2

  公开（公告）日：2019-05-28

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)化合物：或其立体异构体、同分异构体、药学上可接受的盐、多晶型物或溶液，其中所有变量如本文所定义。这些化合物是可用作药物的 GPR40 G 蛋白偶联受体调节剂。
• Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses
  作者：S Watanabe、K Ogawa、T Ohmo、S Yano、H Yamada、T Shirasaka

  DOI：10.1016/0223-5234(94)90029-9

  日期：1994.1

  The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.